EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Long‐Term Functional Outcomes in Immunoglobulin‐Treated Multifocal Motor Neuropathy Evaluated Through the MMN ‐Rasch‐Built Overall Disability Scale

Muhammed A Noushad, Ahmad Al-Areed, Roshan Iqbal, Joumana Freiha, Chinar Osman iD, Yusuf A Rajabally iD

Journal of the Peripheral Nervous System · 2025

DOI: 10.1111/jns.70079 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Muhammed A Noushad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wessex Neurological Centre, University Hospital Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Disability Evaluation, Polyneuropathies, Immunologic Factors, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐term functional outcomes are uncertain in immunoglobulin‐treated multifocal motor neuropathy (MMN).

Methods

We retrospectively studied consecutive subjects with MMN from two neuromuscular centres in Southampton and Birmingham, UK. Initial and latest MMN‐Rasch‐built Overall Disability Scale (MMN‐RODS) scores and latest immunoglobulin doses were collected. Latest dose alterations and resulting MMN‐RODS changes were ascertained.

Results

We included 32 subjects with MMN (14 females and 18 males). Mean age was 60.0 years (SD: 11.7). Over a mean of 6.2 years, MMN‐RODS scores improved in 29 out of 32 (90.6%) subjects and worsened in 3 out of 32 (9.4%) subjects. Mean latest centile MMN‐RODS was improved compared to mean initial centile MMN‐RODS (81.53 [SD: 14.14] vs. 63.47 [SD: 13.82]; p < 0.001). Mean latest immunoglobulin dose was 26.3 g/week (range: 4–70). There were no associations of the latest immunoglobulin dose with age/disease duration/weight/gender/comorbidities/initial disability/latest disability. There were no inter‐centre differences in age/disease duration/weight/gender/comorbidities/initial disability/latest disability. The latest mean immunoglobulin dose was higher in Birmingham than in Southampton (33.9 g/week [SD: 17.1] vs. 18.8 g/week [SD: 8.0]; p = 0.004). Immunoglobulin dose dependency was observed in 16 out of 17 subjects whose last dose alteration was incremental, and in only 3 out of 15 subjects whose last dose alteration was decremental. Dose dependency was demonstrated in a greater proportion of subjects from Birmingham compared to Southampton (13/16 vs. 6/16; p = 0.03).

Conclusions

Function as ascertained by the MMN‐RODS shows sustained improvement over > 6 years with individualised immunoglobulin dosing in most subjects with MMN. The large inter‐centre/inter‐individual dosing and dose dependency variations observed may suggest implications of patient‐ and physician‐related factors, which require further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disability EvaluationPolyneuropathiesImmunologic FactorsImmunoglobulins, IntravenousHumansMaleFemaleMiddle AgedAgedRetrospective StudiesSeverity of Illness IndexAdultTreatment Outcome

Stichwörter der Autor:innen

MMN‐RODSdoseimmunoglobulinminimal clinically important differencemultifocal motor neuropathyoutcomes

Substanzen

Immunologic FactorsImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Wessex Neurological Centre, University Hospital Southampton, Southampton, UK.
  • Inflammatory Neuropathy Service, Department of Neurology, University Hospitals Birmingham, Birmingham, UK.
  • Aston Medical School, Aston University, Birmingham, UK.

ORCID-Profile: Chinar Osman, Yusuf A Rajabally

Zitieren

APA

Noushad, M. A., Al-Areed, A., Iqbal, R., Freiha, J., Osman, C., & Rajabally, Y. A. (2025). Long‐Term Functional Outcomes in Immunoglobulin‐Treated Multifocal Motor Neuropathy Evaluated Through the MMN ‐Rasch‐Built Overall Disability Scale. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70079

Vancouver

Noushad MA, Al-Areed A, Iqbal R, Freiha J, Osman C, Rajabally YA. Long‐Term Functional Outcomes in Immunoglobulin‐Treated Multifocal Motor Neuropathy Evaluated Through the MMN ‐Rasch‐Built Overall Disability Scale. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70079

BibTeX
@article{Noushad2025,
  author = {Noushad, Muhammed A and Al-Areed, Ahmad and Iqbal, Roshan and Freiha, Joumana and Osman, Chinar and Rajabally, Yusuf A},
  title = {Long‐Term Functional Outcomes in Immunoglobulin‐Treated Multifocal Motor Neuropathy Evaluated Through the MMN ‐Rasch‐Built Overall Disability Scale},
  journal = {Journal of the Peripheral Nervous System},
  year = {2025},
  doi = {10.1111/jns.70079}
}
Kostenlos starten →